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Nicotinic ACh receptor (nAChR)
SLURP
SpleenIn 1929, Dale and Dudley described the ﬁrst reported natural occurrence of acetylcholine (ACh) in an animal’s
body. They identiﬁed this ACh in the spleens of horses and oxen, whichwe now know suggests possible involve-
ment of ACh in the regulation of lymphocyte activity and immune function. However, the source and function of
splenic ACh were left unexplored for several decades. Recent studies on the source of ACh in the blood revealed
ACh synthesis catalyzed by choline acetyltransferase (ChAT) in CD4+ T cells. T and B cells, macrophages and
dendritic cells (DCs) all express all ﬁve muscarinic ACh receptor subtypes (mAChRs) and several subtypes of
nicotinic AChRs (nAChRs), including α7 nAChRs. Stimulation of these mAChRs and nAChRs by their respective
agonists causes functional and biochemical changes in the cells. Using AChR knockout mice, we found that
M1/M5 mAChR signaling up-regulates IgG1 and pro-inﬂammatory cytokine production, while α7 nAChR signal-
ing has the opposite effect. These ﬁndings suggest that ACh synthesized by T cells acts in an autocrine/paracrine
fashion at AChRs on various immune cells to modulate immune function. In addition, an endogenous allosteric
and/or orthosteric α7 nAChR ligand, SLURP-1, facilitates functional development of T cells and increases ACh
synthesis via up-regulation of ChATmRNA expression. SLURP-1 is expressed in CD205+DCs residing in the tonsil
in close proximity to T cells, macrophages and B cells. Collectively, these ﬁndings suggest that ACh released from
T cells along with SLURP-1 regulates cytokine production by activating α7 nAChRs on various immune cells,
thereby facilitating T cell development and/or differentiation, leading to immune modulation.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Brief history of acetylcholine identiﬁcation in animal tissues
No one would argue that neurotransmitter acetylcholine (ACh) is
not crucially important to the physiology of animals ranging from nem-
atodes to humans. However, the history of ACh’s discovery demon-
strates that it is much more than just a neurotransmitter [1–4]. This
review was undertaken to facilitate understanding of the important
roles played by non-neuronal cholinergic systems in the regulation of
immune function.
As early as 1867, Adolf von Baeyer chemically synthesizedACh, but it
was then left for nearly four decades without exploration of its biologi-
cal activity [5]. In 1906, Hunt and Taveau [6] discovered the extraordi-
nary strong hypotensive action of ACh in rabbits during their study of
the physiological actions of choline derivatives. This was after Mottarmacology, KitasatoUniversity
Minato-ku, Tokyo 108-8641,
ima.jk@gmail.com,
. This is an open access article underand Halliburton (1899) [7] reported their identiﬁcation of choline in
the cerebrospinal ﬂuid of patients with epilepsy and other nervous sys-
tem diseases, and the fall of blood pressure elicited by choline in dogs,
cats and rabbits. A little later, Henry Dale observed that some ergot ex-
tracts caused a decrease in blood pressure like that elicited by musca-
rine. He then asked a colleague, chemist Arthur J. Ewins, to purify the
chemical entity that caused the hypotension, suspecting the ergot ex-
tracts had been contaminated with muscarine (see Burgen [8]). Ewins
(1914) [9] succeeded in isolating a small amount of the hypotensive
substance fromergot, fruiting bodies of Claviceps purpurea, an ergot fun-
gus, and identiﬁed it physiologically and chemically as ACh. Thiswas the
ﬁrst discovery of ACh in a natural organism. Dale (1914) [10] subse-
quently investigated the physiological effects of various choline esters,
including ACh, and found that they possessed two distinct types of ac-
tivity, muscarinic and nicotinic, and that ACh showed the greatest activ-
ity. Despite these ﬁndings, Dale was initially reluctant to suggest that
ACh functioned as a neurotransmitter, because ACh had not yet been
found as a normal constituent of the animal body (see Todman [11]).
It was Otto Loewi (1921) [12] who provided deﬁnitive physiolog-
ical evidence for chemical transmission of vagus nerve impulses in athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tions. He named the active substance “Vagusstoff,” which was later
pharmacologically identiﬁed by Loewi and Navratil (1926) [13] as
ACh. Finally, in 1929, Dale and Dudley [14] successfully extracted and
chemically identiﬁed ACh as a natural product present in the spleens
of horses and oxen.
On the basis of the results summarized above and other observa-
tions, Dale came to the conclusion that there could be no doubt that
liberation of ACh induced when a preganglionic or postganglionic para-
sympathetic impulses arrived at a synapse plays an essential part in the
transmission of excitation to autonomic ganglion cells or at neuro-
effector junctions. Dale [15,16] suggested the term “cholinergic” to
describe the pre- and postganglionic autonomic neuronal ﬁbers that
transmitted their action through release of ACh, alongwith “adrenergic”
for those that utilized a substance resembling adrenaline. In 1936, The
Nobel Prize in Physiology or Medicine was awarded to Sir Henry Hallett
Dale and Otto Loewi for their discoveries relating to the chemical trans-
mission of nerve impulses. On the other hand, the splenic ACh discov-
ered by Dale is of non-neuronal origin, as there is no evidence for the
cholinergic innervation of the spleen [17–19]. It is therefore important
to recognize that non-neuronal ACh was crucial for the establishment
of the theory of chemical transmission of cholinergic nerve impulses.
2. Rationale for investigating cholinergic regulation of immune
function
The presence of lymphocytes in the spleen and their circulation
through the blood to the spleen were already known by the late 1910s
[20,21]. Therefore, the identiﬁcation of splenic ACh by Dale and Dudley
[14] suggests the possibility that ACh is produced by lymphocytes (T
and B cells), which are signiﬁcant constituents of spleen cells, and that
circulating peripheral blood contains a certain amount of ACh. In the
early 1930s, both German [22,23] and British research groups [24,
25] detected ACh in ox blood. However, large discrepancies among
the groups’ estimations of the ACh content of the blood led to suspen-
sion of the research, most likely due to the absence of a sensitive and
speciﬁcmethod for determining ACh levels, aswell as the lack of proper
acetylcholinesterase (AChE) inhibitors. As a result, the source and func-
tion of splenic ACh were left unexplored for several decades.
Then in 1987, using a sensitive and speciﬁc radioimmunoassay (RIA)
for ACh [26] and paraoxon, an instantaneously active AChE inhibitor, we
detected 456 ± 53 pg/ml of ACh in the plasma of young women (n =
32) [27]. We then subsequently conﬁrmed the presence of ACh in
blood and plasma from various mammalian species, including humans
(Table 1) [27–32]. The ACh levels in bovine blood were about 40 timesTable 1




Holsteina (7) 360.25 ± 59.71 7.14 ± 2.55
Holsteinb (5) 426.11 ± 18.38 5.55 ± 1.47
Japanese blacka (8) 354.30 ± 18.14 15.08 ± 4.53
Chimpanzee (6) 21.50 ± 2.60 1.26 ± 0.07
Dog (10) 1.37 ± 0.23 0.13 ± 0.04
Goat (5) 4.05 ± 0.93 0.22 ± 0.06
Horse (5) 93.8 ± 16.3 0.66 ± 0.23
Human 8.66 ± 1.02 (30) 3.12 ± 0.36 (32)
Porcine (5) 11.70 ± 1.58 15.40 ± 1.58
Rat (10) 1.43 ± 0.20 0.75 ± 0.11
Rabbit (7) 24.50 ± 6.14 0.96 ± 0.11
Sheep (5) 2.04 ± 0.20 0.27 ± 0.05
Values aremeans± SEM. Numbers of samples are in parentheses. Arranged from the data
presented in References [27–32]. aSamples obtained from the ranch afﬁliated to the
Animal Husbandry Experiment Station, Faculty of Agriculture, University of Tokyo.
bSamples obtained from the ranch at Nisshin Flour Milling Co. Ltd.higher than in human, and the levels in equine blood were about 10
times higher. Lower levels of ACh were also detected in the blood and
plasma of other animal species.
3. Origin of blood ACh
In normal Japanese white rabbits, the ACh content of the blood cell
fraction was about 25 times higher than in the plasma (3,722 vs.
140 pg/ml). Under partial inhibition of AChE with neostigmine
(10 μg/kg, iv), nicotine (100 μg/kg, iv) caused an increase of the plasma
ACh concentration that persisted for more than 15 min and was associ-
ated with a gradual reduction in the ACh content of the blood cell frac-
tion [30]. This suggests nicotine induced ACh release from the blood
cells into the plasma.
In another experiment, the plasma ACh content of rabbits immu-
nized with an ACh-immunogen was about 80 times higher than that
in untreated rabbits (11,359 vs. 140 pg/ml of blood, n=8 and 7, respec-
tively), whereas no difference was observed between the ACh contents
of the blood cell fractions from the two groups (4,146 vs. 3,722 pg/ml of
blood, n = 8 and 7, respectively) [30]. This also suggests plasma ACh
originates from blood cells, and that a large portion of plasma ACh
found in the immunized rabbits is bound to the antibody and thus
protected from hydrolysis by AChE. Moreover, using the procedure of
Fonnum [33], the presence of ACh synthesizing activity was detected
in rabbit buffy coat layer cells [34], human mononuclear leukocytes
(MNLs) [35], rat lymphocytes and human leukemic cell lines [36], fur-
ther supporting the idea that ACh detected in plasma originates from
blood cells.
On the basis of the above ﬁndings, we endeavored to identify which
type(s) of blood cells contains ACh by measuring the ACh content of
human MNLs, polymorphonuclear leukocytes (PMNs) and red blood
cells [31]. We found that about 60% of the ACh content in whole blood
is present within MNLs (1263.5 ± 149.0 vs. 731.0 ± 85.8 pg/ml blood,
mean ± SEM, n = 30), and that there is a signiﬁcant correlation be-
tween the ACh content of whole blood and that of MNLs (r = 0.91;
P b 0.001). No ACh was detected in PMNs or red blood cells. These
results indicate that the major portion of blood ACh originates from cir-
culatingMNLs constitutedmainly of lymphocytes and a smallmonocyte
fraction.
3.1. ACh synthesis in T cells
Tucek [37] reported that in peripheral tissues of the rat, ACh is syn-
thesized by both choline acetyltransferase (ChAT, EC 2.3.1.6) and carni-
tine acetyltransferase (CarAT, EC 2.3.1.7). Thismeans that ACh synthesis
in peripheral tissues determined using the method of Fonnum [33]
reﬂects the sum of ChAT and CarAT activities.
3.1.1. ChAT-catalyzed ACh synthesis in T cells
To identify which types of lymphocytes or monocytes synthesizes
and releases ACh, we evaluated the ACh content, ChAT and CarAT activ-
ities, and expression of ChAT mRNA using human leukemic cell lines as
models (Table 2) [38–40]. Different amounts of AChwere detected in all
cell lines tested, except BALL-1 cells, a B cell line, and both ChAT and
CarAT activities were expressed (Table 2). However, expression of
ChAT mRNA was detected only in T cell lines, and the ACh content cor-
related well with ChAT activity (r= 0.960, n = 13), but not with CarAT
activity (r =−0.059, n = 5), suggesting ChAT is responsible for ACh
synthesis in lymphocytes.
Using bromoACh (BrACh), a ChAT inhibitor, andbromoacetylcarnitine
(BrACar), a CarAT inhibitor, with MOLT-3, HSB-2 and CEM T cells, we
examined whether ChAT or CarAT mediates the up-regulation of ACh
synthesis induced by phytohemagglutinin (PHA) stimulation [38]. We
found that 10 μM BrACh reduced ACh synthesis by about 30–50% and
that 100 μM BrACh reduced it by about 50–70%. On the other hand,
100 μM BrACar inhibited ACh synthesis by a maximum of about 30%.
Table 2
ACh content, ChAT and CarAT activities, and ChAT mRNA expression in human leukemic cell lines.








CCRF-CEM T 12.6 ± 0.6 (4) 2.9 ± 0.2 (7) 22.8 ± 4.6 (7) +
HPB-ALL T 0.7 ± 0.1 (13) 0.7 ± 0.1 (3) NT +
HSB-2 T 36.2 ± 3.5 (7) 1.4 ± 0.1 (11) 58.3 ± 15.3 (3) +
HUT-78 T 0.4 ± 0.1 (7) 2.5 ± 0.4 (8) NT +
Jurkat T 8.2 ± 0.4 (4) 4.3 ± 0.8 (3) 17.2 ± 1.9 (6) +
MOLT-3 T 251.5 ± 34.9 (7) 22.4 ± 3.0 (4) 53.3 ± 5.6 (3) +
MOLT-4 T 38.8 ± 5.9 (8) 8.0 ± 1.0 (5) NT +
BALL-1 B ND (4) 0.4 ± 0.2 (3) NT ‐
Daudi B 1.2 ± 0.1 (4) 0.1 ± 0.02 (4) 125.6 ± 44.2 (3) ‐
NALM-6 B 0.04 ± 0.01 (9) 0.1 ± 0.02 (4) NT ‐
NALM-16 prelymphoma 0.3 ± 0.1 (4) 0.1 ± 0.06 (8) NT ‐
REH prelymphoma 0.8 ± 0.01 (3) 0.2 ± 0.03 (6) NT ‐
U937 monocytic 0.02 ± 0.01 (4) 0.2 ± 0.03 (8) NT ‐
Values are means± SEM. Number of experiments is shown in parenthesis. ND, not detectable. NT, not tested. +, positive.−, negative. Rearranged from the data presented in References
[38–40].
129K. Kawashima et al. / International Immunopharmacology 29 (2015) 127–134These results demonstrate that immunological stimulation of ACh syn-
thesis in T cells is dependent on ChAT. They also show that it is
important to differentiate whether ACh synthesis in the target cells is
catalyzed by ChAT or CarAT, and whether it is related to the functional
activity of the cells.
3.1.2. ChAT mRNA expression in T cells
As mentioned, Fujii et al [41] provided the ﬁrst deﬁnitive evidence
for ChAT-catalyzed ACh synthesis in T cells by demonstrating the
expression of ChAT mRNA and protein in the MOLT-3 human leukemic
T cell line. Later, the expression of ChAT mRNA and ACh synthesis were
conﬁrmed in other human leukemic T cell lines, as well as in human
MNLs [39,40] and rat lymphocytes [42].
3.1.3. Mechanisms controlling ACh synthesis in T cells
PHA, which activates T cells via the T cell receptor (TCR)/CD3
complex, increases ACh synthesis by up-regulating ChAT mRNA
expression [39,40]. This ﬁnding suggests immunological stimulation
via TCR/CD3, such as occurs upon interaction of T cells with antigen-
presenting cells, activates lymphocytic cholinergic activity. In addition
to PHA, phorbol 12-myristate 13-acetate, a protein kinase C activator;
A23187 or ionomycin, Ca2+ ionophores; and dibutyryl cAMP (dbcAMP)
all up-regulate ChAT mRNA expression and increase ACh synthesis in
human leukemic T cell lines and human MNLs [43,44]. PHA-induced
ChAT mRNA expression is inhibited by FK506, an immunosuppressant
calcineurin inhibitor, which suggests the involvement of calcineurin-
mediated pathways in the regulation of ChAT transcription [44]. Fur-
thermore, PHA also up-regulates gene expression for M5 muscarinic
ACh receptor (mAChR) and AChE [45]. These ﬁndings lend further
support to the idea that T cell-derived ACh is involved in the regulation
of immune function.
3.2. Mechanism of ACh release from T cells
Although several theories have been proposed, the mechanisms
involved in non-neuronal ACh storage and release remain unclear. Exo-
cytosis is suggested by the identiﬁcation of vesicular acetylcholine
transporter (VAChT) expression in monkey bronchial epithelial cells
and human small cell lung carcinoma cells. On the other hand, active
transport by organic cation transporters has been detected in human
placenta, mouse and human urothelium and mouse bronchial epitheli-
um (see a review by Wessler and Kirkpatrick [4]).
It is not known whether ACh in T cells is stored in vesicles. Fujii
et al [39] did not detect VAChT gene expression in human MNLs,
which argues against a VAChT-based mechanism. An alternative is
that ACh is synthesized in T cells when necessary and then directly
released without storage. Consistent with that idea, Fujii et al [46]detected the mRNA and protein expression of mediatophore in
T cells. Mediatophore is a homo-oligomer of a 16-kDa subunit
homologous with the proteolipid subunit c of vacuolar H+-ATPase
(V-ATPase), which is involved in ACh release at the Torpedo
nerve-electroplaque junction [47]. Moreover, immunological activa-
tion of T cells by PHA up-regulated mediatophore gene expression,
while transfection of a small interference RNA (siRNA) targeting
mediatophore knocked down its expression and reduced ACh re-
lease. ACh release from T cells thus appears to be mediated, at least
in part, by mediatophore.4. Expression of AChRs in immune cells
Most immune cells express subtypes of both mAChRs and nicotinic
ACh receptors (nAChRs), suggesting ACh synthesized and released
from T cells acts on these AChRs via autocrine/paracrine pathways and
is involved in regulating immune function (see reviews [17,48–50]).
Earlier reviews on AChRs in lymphocytes have been published by
Homo-Delarche and Durant [51], Maslinski [52], Nordberg [53] and
Plaut [54]. At the time of their publication, however, neuronally derived
ACh was postulated to activate AChRs on immune cells, despite the fact
that ACh is hydrolyzed by AChE within a few milliseconds after its
release from nerve endings [50].
All ﬁve mAChR subtypes (M1-M5) are expressed on T and B cells,
dendritic cells (DCs) andmacrophages [55,56]. Because of a wide varie-
ty of nAChR subtypes, details of nAChR subtype expression in each
immune cell type are not yet known. However, most immune cells
express mRNAs for neuronal type nAChR subunits, though the patterns
of nAChR subunit expression vary among animal species and immune
cells, and even between developmental stages within a cell [57]. Gene
expression for the α3, α5, α7, α9 and α10 nAChR subunits has been
commonly detected in human T and B cells [49]. However, data on
nAChR subunit expression detected using immunohistochemical tech-
niques should be interpreted with caution, as most commonly available
antibodies against α3, α4, α7, β2 and β4 subunits sometimes generate
false positive results [58].4.1. AChRs and the regulation of immune function
Early studies of the functions of AChRs in immune cells revealed that
stimulation of mAChRs and nAChRs using their respective agonists elic-
ited a variety of functional and biochemical effects, including enhanced
cytotoxicity and increased cGMP formation and intracellular Ca2+
signaling, which suggests AChRs are involved in regulating immune
function (see a review [48]).
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Stimulation of human leukemic T cell (CCRF-CEM) and B cell (Daudi)
lines using ACh or themAChR agonists bethanechol and oxotremorine-M
induced rapid Ca2+ transient followed by extracellular Ca2+-dependent
oscillations and up-regulated c-fos gene expression [59]. These ﬁndings
are consistent with the notion that ACh released from T cells acts on T
and B cell mAChRs via autocrine/paracrine pathways to trigger nuclear
signaling, leading to modulation of immune function.
CD8+ T cells from M1 mAChR-deﬁcient (M1 mAChR-KO) mice
showed a defect in their ability to differentiate into cytolytic T lympho-
cytes [60]. By contrast, nodefectwas observedwhen expansion of CD8+
T cells fromM1 orM5mAChR-KOmicewas stimulated by infectionwith
lymphocytic choriomeningitis virus or vesicular stomatitis virus [61].
Apparently M1 and M5 mAChRs play no role in antiviral immunity.
On the other hand, Fujii et al [62] detected less antigen-speciﬁc IgG1
production in M1/M5 mAChR-KO mice immunized with ovalbumin
than was seen in similarly immunized wild-type mice. Furthermore,
upon stimulation with the antigen, splenic cells from M1/M5 mAChR-
KO mice produced less interferon-γ and interleukin (IL)-6, two pro-
inﬂammatory cytokines, than did splenic cells from wild-type mice.
These ﬁndings suggest M1/M5 mAChRs are involved in up-regulating
the immune response to protein antigens by increasing production of
pro-inﬂammatory cytokines.
4.1.2. nAChRs
Nicotine stimulation of human leukemic T and B cell lines expressing
various nAChR subunits [55] elicits a transient Ca2+ signal that is effec-
tively antagonized by α-bungarotoxin (α-BTX) or methyllycaconitine
(MLA), two selectiveα7 nAChR antagonists, which indicatesα7 nAChRs
are at least partly responsible for the observed Ca2+-signaling [63].
Razani-Boroujerdi et al [64] reported that α7 nAChRs on T cells require
functional T cell receptor (TCR)/CD3 and leukocyte-speciﬁc tyrosine
kinase to mediate nicotine-induced Ca2+-signaling via Ca2+ release
from intracellular stores, which is insensitive to α7 nAChR antagonists
such as α-BTX and MLA. However, a recent study by Fujii et al [65]
showed that MLA reversed the growth attenuation elicited by PHA
and abolished the PHA-induced increase of ACh synthesis in MOLT-3
cells. Given that PHA activates T cells via the TCR/CD3 complex and in-
creases ACh synthesis through up-regulation of ChATmRNA expression
via calcineurin-mediated pathways [39,40], the results suggest that α7
nAChRs linked to TCR/CD3 are sensitive to MLA. The reason for the
apparent differences in α7 nAChR sensitivity to MLA in T cells remains
unclear.
It is well documented that α7 nAChRs mediate down-regulation of
TNF-α synthesis in macrophages, thereby suppressing inﬂammatory
responses [66,67]. Furthermore, Fujii et al [68] showed that production
of antigen-speciﬁc IgG1 antibody and the pro-inﬂammatory cytokines
TNF-α, IFN-γ and IL-6 is elevated in α7 nAChR-KO mice. This suggests
the involvement of α7 nAChRs in the regulation of immune responses
through modulation of cytokine synthesis.
5. SLURP-1 and the regulation of immune function
Endogenously expressed secreted lymphocyte antigen-6/urokinase-
type plasminogen activator receptor-related peptide (SLURP)-1 wasFig. 1. Immunohistochemical staining of SLURP-1, CD205, CD4, CD68, CD11c and HLA-DOβ in
tonsil (hematoxylin and eosin staining). A2: SLURP-1 immunohistochemistry with avidin-bio
seen mainly in the interfollicular zone surrounding the germinal center of the tonsil. A4: High
and CD205 immunoreactivities in the tonsil. B1: SLURP-1 immunoreactivity in the interfollicula
noreactivities. Some CD205+ cells are also SLURP-1+. B4: Enlarged image of the boxed area in B
the interfollicular zone. C2: CD4 immunoreactivity. C3:Merged image of the SLURP-1 andCD4 im
of the boxed area in C3. D. SLURP-1 and CD68 (monocyte/macrophage) immunoreactivities in
activity. D3: Merged image of the SLURP-1 and CD68 immunoreactivities. D4: Enlarged image
cells. E. SLURP-1 and CD11c (certain DC subtypes) immunoreactivities in the tonsil. E1: SLURP
image of the SLURP-1 and CD11c immunoreactivities. E4: Enlarged image of the boxed area in
DOβ (B cells) immunoreactivities in the tonsil. F1: SLURP-1 immunoreactivity in the interfoll
DOβ immunoreactivities. F4: Enlarged image of the boxed area in F3. The SLURP-1+ cells are inﬁrst puriﬁed from human blood and identiﬁed by Adermann et al [69].
SLURP-1 acts as a positive allosteric ligand, potentiating the action of
ACh at α7 nAChRs in Xenopus oocytes expressing recombinant human
α7 nAChRs [70], or as an orthosteric agonist forα7 nAChRs, stimulating
pro-apoptotic activity and differentiation in human keratinocytes [71].
SLURP-1 gene mutations have been detected in patients with Mal de
Meleda (MdM), a rare autosomal recessive skin disorder characterized
by transgressive palmoplantar keratoderma [72].
SLURP-1 mRNA is expressed in most immune organs, including
the thymus and spleen [73], as well as in peripheral blood MNLs, DCs
and macrophages, suggesting a role for SLURP-1 in the regulation of
immune function [56,73]. Indeed, evidence from a study using T cells
from MdM patients with a genetic SLURP-1 mutation [74] suggest
SLURP-1 plays a crucial role in the T cell activation.
Fujii et al [65] detected SLURP-1 expression in CD205+ DCs (Fig. 1A,
B) residing mainly in the interfollicular zone surrounding the germinal
center of human tonsils. Furthermore, tonsillar SLURP-1+CD205+ DCs
are surrounded by CD4+ T cells and other immune cells expressing
markers for monocyte/macrophages (CD68) [75], DCs (CD11c) [76]
and B cells (HLA-DOβ) [77] (Fig. 1C–F),which suggests close interaction
between SLURP-1+ DCs and CD4+ T cells, certain DC subtypes, macro-
phages and B cells during antigen presentation and other immunologi-
cal reactions. A recent study by Fukuya et al [78] on the critical role of
CD205+ DCs in the regulation of T cell immunity suggests SLURP-1
and ACh released from T cells act via α7 nAChRs to regulate immune
function.
Recombinant SLURP-1 (0.5 μg/ml) attenuates proliferation of MOLT-
3 cells and human blood MNLs, and increases the ACh content of the
cells by up-regulating ChAT expression, all of which are abolished by
MLA (Fig. 2) [65]. This suggests SLURP-1 activates cholinergic transmis-
sion by potentiating ACh synthesis and its action atα7 nAChRs, thereby
facilitating the functional development of T cells. Chernyavsky et al [79]
recently reported that SLURP-1 exerts anti-inﬂammatory effects by
down-regulating TNF-α production in T cells and IL-1β and IL-6
secretion from macrophages. Taken together, these ﬁndings suggest
activation ofα7 nAChRs in T cells up-regulates ACh synthesis, which fa-
cilitates further action by ACh in the presence of SLURP-1 atα7 nAChRs
expressed on DCs andmacrophages, leading tomodiﬁcation of cytokine
synthesis.
6. α7 nAChRs and the regulation of immune function
The schematic diagram in the Supplementary data (Fig. 3) illustrates
theﬁndings obtained so far on the non-neuronal cholinergic system and
its potential role in T cell development and/or differentiation. CD4+ T
cells express most cholinergic components, including ChAT, mAChRs
and nAChRs, including α7 nAChRs, which is sufﬁcient to constitute an
independent cholinergic system within the immune system [49,50].
DCs, macrophages, B cells also express both mAChRs and nAChRs, in-
cluding α7 nAChRs, and CD205+ DCs express SLURP-1 (Fig. 2) [56,65].
As described, antigen presentation between naïve CD4+ T cells and
SLURP-1+ DCs activates T cells, leading to increased ACh synthesis as
the result of up-regulated ChAT expression (Fig. 3). ACh released from
T cells then acts in an autocrine/paracrine fashion atα7 nAChRs tomod-
ulate cytokine synthesis in T cells, DCs, macrophages and B cells. AChhuman tonsil. A. SLURP-1 immunoreactivity. A1: Low-magniﬁcation images of a palatine
tin-peroxidase staining. A3: Enlarged image of the boxed area in A2. SLURP-1+ cells are
er power image of SLURP-1 labeling. SLURP-1+ cells have a DC-like structure. B. SLURP-1
r zone. B2: CD205 immunoreactivity. B3: Merged image of the SLURP-1 and CD205 immu-
3. C. SLURP-1 and CD4 immunoreactivities in the tonsil. C1: SLURP-1 immunoreactivity in
munoreactivities. The SLURP-1+ cells are surrounded by CD4+T cells. C4: Enlarged image
the tonsil. D1: SLURP-1 immunoreactivity in the interfollicular zone. D2: CD68 immunore-
of the boxed area in D3. The SLURP-1+ cells are localized in close proximity to the CD68+
-1 immunoreactivity in the interfollicular zone. E2: CD11c immunoreactivity. E3: Merged
E3. The SLURP-1+ cells are in close proximity to the CD11c+ cells. F. SLURP-1 and HLA-
icular zone. F2: HLA-DOβ immunoreactivity. F3: Merged image of the SLURP-1 and HLA-
close proximity to the HLA-DOβ+ cells. Adopted from Fujii et al [65] with modiﬁcations.
131K. Kawashima et al. / International Immunopharmacology 29 (2015) 127–134
Fig. 2. Effects of SLURP-1 and methyllycaconitine (MLA), a speciﬁc α7 nAChR antagonist, on (A) ChAT gene expression and (B) intracellular ACh content and release in MOLT-3 cells and
human MNLs. Cells were incubated for 48 h with SLURP-1 (0.5 μg/ml) and/or MLA (100 nM). A: ChAT mRNA expression analyzed using RT-PCR. The expected size of the ChAT RT-PCR
product was 652 bp. The bars represent means ± SEM (n = 3) of the levels of ChAT mRNA normalized to the level of GAPDH mRNA and expressed as a percentage of Control.
*P b 0.05 vs. Control (Student’s t-test). B: ACh was measured within the cells and in conditioned medium using a speciﬁc RIA [26] (Kawashima et al, 1980). All assays were carried out
in triplicate. Data are means ± SEM (n = 5). *P b 0.05 vs. Control (Tukey’s t-test). Adopted from Fujii et al [65] with modiﬁcation.
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synthesis of ACh, as shown in Fig. 2. Then via α7 nAChRs on macro-
phages, ACh down-regulates synthesis of pro-inﬂammatory cytokines
such as TNF-α [19,66,67,80]. SLURP-1 released from CD205+SLURP-
1+ DCs should potentiate the action of ACh at α7 nAChRs on macro-
phages, enhancing its modulation of pro-inﬂammatory cytokine pro-
duction. Oloffson et al [80] suggested α7 nAChRs expressed in non-T
cell bone marrow-derived immune cells, together with splenic ACh-
producing T cells, are necessary for normal function of the inﬂammatory
reﬂex leading to modulation of TNF-α synthesis. As described above,
however, α7 nAChRs on T cells also act within the inﬂammatory reﬂex
by stimulating ACh synthesis and release, thereby regulating pro-
inﬂammatory cytokine production by macrophages [65].
Chernyavsky et al [81] showed that SLURP-1 up-regulates NF-
κB expression in Het-1A human oral keratinocytes via α7 nAChR-
mediated pathways, which involve both ionic events and activation of
protein kinases. It is therefore reasonable to consider that ACh/SLURP-
1-induced activation of α7 nAChRs on immune cells is also mediated
via two signaling systems entailing both ionic events and protein kinase
cascades.
Moriwaki et al (in preparation) discovered that IL-22 up-regulates
expression of SLURP-1 mRNA in human keratinocytes, and that this
effect is suppressed by S3I-201, an inhibitor of the transcription factor
STAT3, aswell as by siRNA targeting STAT3. CD4+ T cells, whichproduce
IL-17, also have the ability to synthesize IL-22 [82]. Thus, IL-22 released
from T cells should stimulate SLURP-1 production, leading to further
activation of α7 nAChRs on immune cells residing in the vicinity of
CD205+SLURP-1+ DCs.
The spleen, lymph nodes and tonsils are secondary lymphoid organs
and have many functional and structural similarities, such as lymphoid
follicles, a germinal center and amarginal zone containing T and B cells,
DCs and macrophages. It would therefore be reasonable to extrapo-
late the ﬁndings made in tonsils to the spleen and lymph nodes.
Furthermore, tonsils were recently shown to play a key role in T cell
development [83].
Taken together, the accumulated evidence suggests that α7 nAChRs
on immune cells play key roles in the regulation of immune function by
modulating the synthesis of various cytokines as well as ACh, thereby
regulating the development and differentiation of naïve CD4 T cells
into Th1/Th2/Th17 and regulatory T cells.At present, little is known about the effects exerted by ACh via α7
nAChRs on DCs and B cells, other than induction of Ca2+ signaling in B
cells [63]. However, it is known that antigen-speciﬁc IgG1 production
is up-regulated in α7 nAChR-KO mice [68] and that α7 nAChRs and
other nAChR subunits are involved in the regulation of B cell develop-
ment and activation [84].
As described above, the role of α7 nAChRs in the regulation of pro-
inﬂammatory cytokine production and immune function has been
investigated primarily in studies using α7 nAChR-KO mice [66,68].
However, because human T and B cells express mRNAs encoding both
α7 and α9 nAChR subunits [49], and because both α-BTX and MLA
exhibit high afﬁnity not only for α7 nAChRs but also for α9 nAChRs
[85,86], we cannot rule out the possibility that the effects of ACh, nico-
tine and SLURP-1 that are blocked by α7 nAChR antagonists such as
α-BTX and MLA may also be mediated in part by α9 nAChRs.7. Conclusion
Viewed in the context of what we now know, it is apparent that the
splenic ACh identiﬁed by Dale and Dudley (1929), the ﬁrst ACh discov-
ered naturally occurring in an animal’s body, was likely involved in
regulating immune function. Several decades later, we discovered
ChAT-catalyzed ACh synthesis in T cells, a signiﬁcant constituent of
spleen cells, and the up-regulation of ChAT gene expression through im-
munological activation of T cells. Immune cells express all ﬁve mAChR
subtypes and several nAChR subtypes, including α7 nAChRs. Stimula-
tion of these mAChRs and nAChRs by their respective agonists elicits
functional and biochemical changes in immune cells, suggesting the in-
volvement of ACh synthesized by T cells in the regulation of immune
function. Furthermore, studies of AChR-KO mice showed that M1/M5
mAChRs mediate up-regulation of antigen-speciﬁc IgG1 and pro-
inﬂammatory cytokine production,whileα7 nAChRsmediate the oppo-
site effect. In addition, a recently discovered endogenous α7 nAChR
allosteric and/or orthosteric ligand, SLURP-1, facilitates functional de-
velopment of T cells via α7 nAChR-mediated pathways, leading to in-
creases in ACh synthesis. Collectively, these ﬁndings suggest that,
acting via α7 AChRs, ACh released from T cells contributes to the regu-
lation cytokine production in immune cells, thereby modulating T cell
development and/or differentiation.
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